Put simply, I study how patients’ beliefs and expectations about their treatment and disease can be changed through brief interventions and tailored communication strategies. 

The placebo effect, where patients experience improvements solely due to their belief in treatment efficacy, is integral to my research. 

I am currently investigating how psychological interventions (including those that are digitally-delivered) alter physiological mechanisms. In one ongoing study, we are exploring how interventions that instill more helpful mindsets about cancer (e.g., cancer is manageable and not a catastrophe), can impact immune function.

While conducting hospital-based research, I noticed that patients rarely make treatment decisions in isolation or navigate their medical journey alone. 

Yet, most of our interventions in psychology tend to focus on the individual, overlooking the possible impact of the social environment. 

My second line of research aims to understand how the social environment (e.g., interpersonal relationships) can be harnessed to improve treatment decisions and other outcomes. I am particularly interested in understanding how relationships impact the effects of psychological interventions, such as by amplifying or diminishing outcomes.

A key focus of my research has been on improving biosimilar uptake. 

Biosimilars are a class of drugs that are manufactured after the patent for a reference biologic (biopharmaceutical) has expired. As such, they provide an exciting opportunity for competition, innovation, and improved access for patients. However, some patients and providers have concerns about their safety, efficacy and quality. 

My research includes interventions that aim to reduce hesitancy towards biosimilars, and strategies for improving the logistical aspects of brand changes.

See 'Interviews and Media' for my perspectives on the biosimilar boom in the U.S.